Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects

Author： Bence Aimee K.   Anderson Eric B.   Halepota Maqbool A.   Doukas Michael A.   DeSimone Phillip A.   Davis George A.   Smith Deborah A.   Koch Kevin M.   Stead Andrew G.   Mangum Steve   Bowen Carolyn J.   Spector Neil L.   Hsieh Showchien   Adams Val R.  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.1, 2005-01, pp. : 39-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety, Tolerability and Pharmacokinetics of Dalcetrapib Following Single and Multiple Ascending Doses in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled, Phase I Study

By Derks Michael   Anzures-Cabrera Judith   Turnbull Lynn   Phelan Mary  

Clinical Drug Investigation, Vol. 31, Iss. 5, 2011-05 ,pp. : 325-335

Adis International

Access to resources Recommend Favorite

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of an Omega‐3‐Carboxylic Acid Formulation in Healthy Male Japanese Subjects: A Phase 1 Single‐Blind, Randomized, Placebo‐Controlled Trial

By  

Clinical Pharmacology In Drug Development, Vol. 7, Iss. 2, 2018-02 ,pp. : 177-187

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Aliskiren in Healthy Chinese Subjects: A Randomized, Single-Blind, Parallel-Group, Placebo-Controlled Study

By Hu Pei  

Clinical Drug Investigation, Vol. 30, Iss. 4, 2010-04 ,pp. : 221-228

Adis International

Access to resources Recommend Favorite

Phase Ib Single- and Multiple-Dose Pharmacokinetic Study of Oral NV-52 in Healthy Volunteers

By Howes Laurence G.  

Drugs in R&D, Vol. 9, Iss. 3, 2008-01 ,pp. : 159-166

Adis International

Access to resources Recommend Favorite

Pharmacokinetics and safety of escalating single and repeat oral doses of GW420867X, a novel non-nucleoside reverse transcriptase inhibitor

By Moore K.H.P.   Cass L.M.   Dallow N.   Hardman T.C.   Jones A.   Boyce M.   Prince W.T.  

European Journal of Clinical Pharmacology, Vol. 56, Iss. 11, 2001-01 ,pp. : 805-811

Springer Publishing Company

Access to resources Recommend Favorite